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Background: There has been worldwide interest in the safety of the pandemic influenza A 
(H1N1p) vaccines, although limited data are available from the vaccine recipients’   perspective. 
This evaluation was designed to collect data from people who had received an influenza vac-
cination during the 2009–2010 season using a web-based data collection tool supplemented by 
telephone reporting (PROBE).
Methods: People scheduled to receive the influenza A (H1N1p) or seasonal influenza vaccines 
were recruited through media advertising and campaigns throughout the West of Scotland. 
Vaccine recipients participated in the evaluation by answering demographic and side effect 
questions using PROBE methodology on the day of the immunization, after 3 days, 8 days, 
6 weeks, 12 weeks, and 26 weeks.
Results: A total of 1103 vaccine recipients including 134 young children (0–4 years) participated 
in the evaluation; 694 (63%) received H1N1p vaccine only, 135 (12%) seasonal vaccine only, 
224 (20%) both H1N1p and seasonal vaccines, and 50 (5%) received H1N1p or seasonal vaccine 
with a non-influenza vaccine (eg, travel or pneumococcal). Overall, 42% of recipients reported 
experiencing a side effect after their baseline vaccination; the most commonly reported were 
general and arm side effects (.20%). Injection site discomfort/pain and flu-like symptoms were 
reported by 57% and 24% of recipients, respectively. A significantly higher proportion of the 
960 H1N1p vaccine recipients experienced a side effect (44% vs 27%, P , 0.001) or injection 
site discomfort/pain (61% vs 26%, P , 0.001) than those receiving seasonal influenza vaccines. 
Female sex and H1N1p vaccination were associated with a significantly higher risk of injec-
tion site discomfort/pain, whereas the 70+ age group was associated with a significantly lower 
risk. H1N1p vaccine was well tolerated by children under 5 years with side effects reported at 
a similar frequency to that found in the total population.
Conclusions: Safety and tolerability data from influenza vaccine recipients including young 
children (via parents/carers) can be effectively collected using an online questionnaire with 
a telephone option (PROBE). The influenza A (H1N1p) vaccine was well tolerated, but was 
associated with more local short-term reactions than the seasonal influenza vaccine.
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Introduction
The first outbreak of the influenza A (H1N1p) virus (swine flu) occurred in Mexico in April 
2009. The first cases in the UK were confirmed shortly afterwards in late April 2009. As 
the virus spread worldwide, a global pandemic influenza (phase six) was declared by the 
World Health Organization (WHO) on 11 June 2009 and lasted until August 2010.1,2 Most 
people infected with the H1N1p virus developed only a mild illness, which generally lasted 
for about 1 week. However, there was a risk of serious illness, developing   complications Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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such as acute respiratory distress syndrome caused by viral 
pneumonia and death with H1N1p infection.
A vaccine to prevent influenza A (H1N1p) was urgently 
required to protect people likely to be at greater risk of seri-
ous illness such as the very young, elderly, pregnant women, 
and those with underlying health problems. Two vaccines 
against the A (H1N1p) 2009 strain of the influenza virus 
were purchased by the UK government and used in the UK 
vaccination program for the 2009–2010 season. These were 
an AS03B adjuvanted split virion vaccine (Pandemrix®, 
GlaxoSmithKline Vaccines, Belgium)3 and a non-adjuvanted 
whole virion vaccine (Celvapan®, Baxter Vaccines, Austria).4 
The vaccines were both approved under ‘exceptional circum-
stances’ by the European Medicines Agency (EMA) after 
they had been authorized initially as ‘mock-up’ vaccines and 
converted to influenza A (H1N1p) vaccines once the respon-
sible strain of influenza had been identified. The European 
regulators evaluated their safety profiles by comparing the 
limited clinical trial data available with that of the extensive 
safety database for influenza vaccines, including data from 
‘mock up’ vaccines containing H5N1 antigen.5
The public were educated about swine flu and the vac-
cination program through the UK health and public infor-
mation bodies,6 and all UK households were sent leaflets. 
The vaccination program focused on frontline health and 
social care workers and those groups of people at high risk 
of developing serious illness or complications (Table 1). The 
main differences to the seasonal flu target audience were 
the inclusion of all children aged 6 months to 5 years in the 
H1N1p campaign, and less emphasis on residential homes 
and carers of dependents.
Uptake rates for influenza A (H1N1p) vaccination were 
lower than expected. For example, in Scotland, the estimated 
cumulative uptake of the vaccine in the clinically at risk 
groups was 54.3% for the under 65 year group which included 
  pregnant women, and 56.1% in the 65 and over (to end of 
February 2010).7 Reasons given for non-immunization include 
possible side effects and concern about the adequacy of testing. 
The most common side effects with the vaccines were reported 
to be redness, pain, swelling, or hardness near the intramuscu-
lar injection site, muscular and joint pain, fever, fatigue, and 
headache.3,4 Neurological disorders such as encephalomyelitis, 
neuritis, and Guillain–Barré syndrome have been reported very 
rarely (,1/10,000) during post-marketing surveillance.3,4
There are significant risks associated with H1N1p 
  infection. WHO figures show that 1%–10% of clinical 
cases of influenza A (H1N1p) needed hospitalization, with 
10%–25% of those hospitalized requiring admission to 
intensive care units (ICUs).8 A small proportion (2%–9%) 
of patients hospitalized with H1N1p infection die. Although, 
most cases of infection occurred in teenagers and young 
adults, the rates of hospitalization were highest in very young 
children.8 In the UK, there have been 474 deaths due to the 
virus, to 30 September 2010.9
There has been enormous interest in the safety evaluation 
of pandemic A (H1N1p) 2009 vaccines. In order to monitor 
the vaccination programs, many existing national systems for 
signal detection, strength, verification, and confirmation have 
been improved and new systems instigated. For example, the 
US Food and Drug Administration has established a number 
of tools such as existing spontaneous reporting systems 
(Vaccine Adverse event reporting system [VAERs]), single 
database links (Vaccine safety datalink [VSD]), and separate 
database links (post licensure rapid immunization safety 
monitoring [PRISM]). The limited, publicly available, data 
to date indicate that the vaccines have a very positive benefit-
risk profile with the benefits of reduced disease outweighing 
any safety risks of vaccination.
Nevertheless, many were anxious about the side effects 
associated with influenza vaccinations, particularly as these 
issues have been widely discussed in the media. The aim 
of this evaluation was to determine the real-life incidence 
of any side effects by collecting information directly from 
the recipients of pandemic A (H1N1p) vaccine and other 
influenza vaccines. The evaluation of side effects following 
the concurrent use of pandemic A (H1N1p) with seasonal 
influenza vaccine is of particular interest.
Methods
study design
Patient Reported Outcomes Based Evaluation (PROBE) 
methodology, which consisted of a web-based system 
Table  1  UK  vaccination  program  for  the  influenza  A  H1N1p 
virus
Phase 1 immunization commenced 21 October 2009
Frontline health care and social care workers
Clinical risk groups, in order of priority:
•   individuals aged 6 months and up to 65 years in the current seasonal 
flu vaccine clinical at-risk groupsa
• Pregnant women
• household contacts of immunocompromised individuals
•   People aged 65 and over in the current seasonal flu vaccine clinical 
at-risk groupsa
Phase 2 immunization commenced 20 November 2009
• Children over 6 months and under 5 years of age
Notes: aClinical, at high risk groups include those with chronic respiratory, chronic 
heart, chronic renal, chronic liver or chronic neurological diseases, diabetes mellitus, 
and those who are immunosuppressed by disease or treatment.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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supplemented by telephone reporting, was used to collect 
naturalistic data from patients who had received vaccination 
for H1N1p (swine flu) or seasonal influenza during the UK 
vaccination program for the 2009–2010 season.
Media advertising (newspaper, TV, and radio) and 
campaigns in public places such as libraries, children’s 
nurseries, and GP surgeries, as well as workplaces where 
H1N1p vaccination was being implemented, were used to 
recruit people.
Patient reported outcomes based  
evaluation (PROBE)
Individuals who had received an influenza vaccination were 
asked to participate in the evaluation by logging onto a secure 
website (https://www.myflujag.com/) of Patients Direct, 
Glasgow, UK. Electronic consent was obtained before indi-
viduals were asked to complete a questionnaire, which took 
less than 5 minutes on the day of immunization, and was 
followed up at day 3, day 8, week 6, week 12, and week 26. 
The longer-term follow up was to try to capture rare events 
such as Guillain–Barré syndrome.
Respondents were questioned about demographic 
details, the vaccine they had received, and whether they had 
received a previous swine flu or seasonal flu vaccination. 
  Unfortunately, the exact type of H1N1p vaccine received 
was not raised during questioning, and recorded.   However, 
we know that the Medicines and Healthcare Products 
  Regulatory Agency reports of adverse events attributed 99% 
to use of Pandemrix and 1% to Celvapan (where the vaccine 
was known). Additionally, the government purchase and 
recommendations were to use Pandemrix unless there was 
a contraindication such as egg allergy. It is therefore likely 
that .95% of recipients of the H1N1p vaccination had 
received the Pandemrix vaccine. The participants were asked 
directly whether they had experienced any pain or discomfort 
at the injection site and/or if they had experienced any side 
effects from the vaccination. The recording of a side effect 
led to a side effect cascade asking which body areas were 
associated with the side effects: general, head, chest, stomach, 
arm, leg, skin, bladder, sexual, emotional, and other, followed 
by specific side effects in each category such as headache, 
nausea, and vomiting. The action taken due to a reported side 
effect and its duration were also requested.
Individuals with no access to the Internet or who preferred 
to use the telephone could participate in the evaluation by 
using a Freephone number and speaking to a research nurse. 
The questions were given in the same structured format, 
with the research nurse entering the data directly into the 
web-based survey database. Alternatively, the research nurse 
provided telephone support on specific questions raised by 
the patient, and the patient completed the survey online.
Sample size and statistical methods
No formal sample size calculations were completed before 
the study. To illustrate the power of the study, given that of 
143 individuals who did not receive the H1N1p vaccination 
at baseline, 25.9% experienced discomfort or pain, with 
960 individuals receiving a H1N1p vaccination, there was 
90% power to have detected an increase in the rate of dis-
comfort or pain to 40%.
Data collected on the day of the immunization and 
after 3 and 8 days are summarized together as baseline 
data.   Statistical analyses were performed using SPLUS for 
  Windows (v 8.1; TIBCO Software Inc, Palo Alto, CA).
Fisher’s exact test or Kruskal–Wallis test were used to 
test for significance of any differences between vaccines 
or vaccine combinations. Associations between discomfort 
or pain after the baseline vaccination and predictors (age, 
sex, chronic illness group, H1N1p vaccine, and seasonal flu 
vaccine) were determined using univariate and multivariate 
logistic regression. Odds ratios with 95% confidence intervals 
and P values are presented.
Results
Respondents
A total of 1103 vaccine recipients (448 males, 655 females) 
including 134 young children (0–4 years) through their 
parents or carers participated in the evaluation between 
2 November 2009 and 31 May 2010 with 697 (63%) using 
the web-based mode and 406 (37%) using the telephone. 
Of the 1103 recipients, 694 (63%) received H1N1p vaccine 
only, 135 (12%) seasonal vaccine only, 224 (20%) both 
H1N1p and seasonal vaccines, and 50 (5%) received H1NI 
or seasonal vaccine along with a non-influenza vaccine such 
as a travel or pneumococcal vaccine at baseline (Table 2). 
Half (547/1103) of those vaccinated had a chronic illness. 
Overall, 960 respondents received the H1N1p influenza vac-
cine either alone (n = 694), in combination with a seasonal 
influenza vaccine (n = 224), or in combination with another 
vaccine (n = 42). Of the 960 H1N1p vaccine recipients, 
501 (52%) had a chronic illness and 132 (14%) were in the   
0–4 age group (Table 2).
The groups receiving the vaccines were significantly 
different at baseline for age and existing chronic illness 
(Table 3). The main age difference being the H1N1p-only 
group, with the highest proportion of under 5 year olds Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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(123 out of 134 recruited). The main outcomes have been 
run by different age splits (eg, ,5 vs 5+, ,18 vs 18+) and 
the sub group results mirror the overall group with no change 
to the conclusions (Tables A6 and A7).
The groups were similar for sex split. The percentage 
who received a previous vaccination was expected to be 
different, because the H1N1p vaccine was introduced after 
the start of the seasonal flu vaccination program and there-
fore many had already received this vaccination. Previous 
vaccination was not a predictor of pain/discomfort as seen 
in Table 7.
Twenty-six week follow-up data were obtained from 
more than half of the respondents (577, 52%; see Table A1 
for follow-up rates).
side effects
Overall, 42% of respondents reported experiencing a side 
effect after their baseline vaccination. There was a signifi-
cant difference between the H1N1p influenza vaccine and 
seasonal vaccine recipients. Of the 960 recipients of an 
H1N1p influenza vaccine, a significantly higher proportion 
(425, 44%) experienced a side effect compared with those 
who received only the seasonal influenza vaccine (38/143, 
27%, P , 0.001; Table 4). Greater numbers of side effects 
were also reported by respondents who had received H1N1p, 
compared with those who had not (P , 0.001; Table 4). The 
most commonly reported side effects were muscle wasting 
and headache (.9%).
Muscle weakness and joint pain were reported by a 
significantly higher proportion of respondents receiving 
the combination of H1N1p and seasonal influenza vac-
cines than H1N1p or seasonal influenza vaccination alone 
(Table 4).
Flu-like symptoms were reported by 24% (195/824) of 
all recipients responding to this question with 2% (17/824) 
having to take time off work due to their symptoms.   However, 
Table 2 Demographic and clinical characteristics of respondents by combinations and types of influenza vaccines received at baseline
Number (% of total) of respondents
H1N1p  
only
Seasonal  
only
H1N1p and  
seasonal
H1N1p/seasonal  
and other
Overall H1N1p1 Seasonal1 Other1
Respondents 694 (62.9%) 135 (12.2%) 224 (20.3%) 50 (4.5%) 1103 960 (87.0%) 382 (34.6%) 50 (4.5%)
Data collection method
  Web 395 (56.7%) 83 (11.9%) 185 (26.5%) 34 (4.9%) 697 607 (87.1%) 289 (41.5%) 34 (4.9%)
  Phone 299 (73.6%) 52 (12.8%) 39 (9.6%) 16 (3.9%) 406 353 (86.9%) 93 (22.9%) 16 (3.9%)
sex
  Male 287 (64.1%) 60 (13.4%) 81 (18.1%) 20 (4.5%) 448 386 (86.2%) 153 (34.2%) 20 (4.5%)
  Female 407 (62.1%) 75 (11.5%) 143 (21.8%) 30 (4.6%) 655 574 (87.6%) 229 (35.0%) 30 (4.6%)
Age (years)
  0–4 123 (91.8%) 2 (1.5%) 7 (5.2%) 2 (1.5%) 134 132 (98.5%) 9 (6.7%) 2 (1.5%)
  5–29 42 (58.3%) 9 (12.5%) 18 (25.0%) 3 (4.2%) 72 63 (87.5%) 28 (38.9%) 3 (4.2%)
  30–49 111 (47.8%) 31 (13.4%) 77 (33.2%) 13 (5.6%) 232 200 (86.2%) 115 (49.6%) 13 (5.6%)
  50–69 229 (54.1%) 65 (15.4%) 101 (23.9%) 28 (6.6%) 423 352 (83.2%) 180 (42.6%) 28 (6.6%)
  70+ 189 (78.1%) 28 (11.6%) 21 (8.7%) 4 (1.7%) 242 213 (88.0%) 50 (20.7%) 4 (1.7%)
Chronic illness 321 (58.7%) 43 (7.9%) 154 (28.2%) 29 (5.3%) 547 501 (91.6%) 212 (38.8%) 29 (5.3%)
Previous h1n1p  
flu vaccination
13 (37.1%) 13 (37.1%) 4 (11.4%) 5 (14.3%) 35 20 (57.1%) 20 (57.1%) 5 (14.3%)
Previous seasonal  
flu vaccination
433 (96.2%) 2 (0.4%) 1 (0.2%) 14 (3.1%) 450 447 (99.3%) 4 (0.9%) 14 (3.1%)
Note: 1Caution – numbers do not total to sample size due to all counts included.
Table 3 Demographic and clinical characteristics of respondents 
by  combinations  and  types  of  influenza  vaccines  received  at 
baseline (within group)
H1N1  
only
Seasonal  
only
H1N1 and  
seasonal
P valuea
n 694 135 224
sex
  Male 287 (41.4%) 60 (44.4%) 81 (36.2%) = 0.247
  Female 407 (58.6%) 75 (55.6%) 143 (63.8%)
Age
  0–4 123 (17.7%) 2 (1.5%) 7 (3.1%) ,0.001
  5–29 42 (6.1%) 9 (6.7%) 18 (8.0%)
  30–49 111 (16.0%) 31 (23.0%) 77 (34.4%)
  50–69 229 (33.0%) 65 (48.1%) 101 (45.1%)
  70+ 189 (27.2%) 28 (20.7%) 21 (9.4%)
Chronic  
illness
321 (46.3%) 43 (31.9%) 154 (68.8%) ,0.001
Prev h1n1  
vaccination
13 (1.9%) 13 (9.6%) 4 (1.8%) ,0.001
Prev seasonal  
vaccination
433 (62.4%) 2 (1.5%) 1 (0.4%) ,0.001
Note: aP value from Fisher exact test.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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there were no significant differences in the incidence of 
  flu-like symptoms, absenteeism, or duration of time taken 
off due to flu-like symptoms between the H1N1p and sea-
sonal vaccine or between the different vaccine combinations 
(Table 5). Vaccine recipients were specifically asked whether 
they had any pain or discomfort at the injection site and 57% 
reported that they had some discomfort or some pain after 
the baseline vaccination. A significantly higher proportion of 
H1N1p than seasonal influenza vaccine recipients reported 
local discomfort/pain (61% vs 26%, P , 0.001). The duration 
Table 4 Number (%) of respondents recording any side effects after baseline influenza vaccination
Side effects H1N1p  
only
Seasonal  
only
H1N1p and  
seasonal
H1N1p/ 
seasonal  
and other
Overall P valued H1N1p  
total
Not H1N1p  
total
P valuee
n (nMissing) 694 (0) 135 (0) 224 (0) 50 (0) 1103 (0) 960 (0) 143 (0)
Anya 314 (45.2%) 35 (25.9%) 94 (42.0%) 20 (40.0%) 463 (42.0%) 0.001 425 (44.3%) 38 (26.6%) ,0.001
Any (including  
pain/discomfort)b
511 (73.6%) 61 (45.2%) 167 (74.6%) 33 (66.0%) 772 (70.0%) ,0.001 708 (73.8%) 64 (44.8%) ,0.001
n side effects  
(including pain/ 
discomfort)/ 
respondent
2.0 (2.8) 0.9 (2.0) 2.4 (3.7) 2.5 (4.5) 2.0 (3.0) ,0.001 2.1 (3.1) 1.0 (2.1) ,0.001
Side effectc
n (nMissing) 688 (6) 131 (4) 220 (4) 49 (1) 1088 (15)
Muscle wasting 70 (10.2%) 12 (9.2%) 21 (9.5%) 5 (10.2%) 108 (9.9%) 0.985
headache 76 (11.0%) 7 (5.3%) 26 (11.8%) 2 (4.1%) 101 (9.3%) 0.090
Lethargy/tiredness 58 (8.4%) 7 (5.3%) 26 (11.8%) 6 (12.2%) 97 (8.9%) 0.148
sleeping problems 49 (7.1%) 4 (3.1%) 16 (7.3%) 3 (6.1%) 72 (6.6%) 0.352
Fever 35 (5.1%) 4 (3.1%) 13 (5.9%) 2 (4.1%) 54 (5.0%) 0.701
Loss of appetite 39 (5.7%) 3 (2.3%) 10 (4.5%) 2 (4.12%) 54 (5.0%) 0.462
Muscle weakness 24 (3.5%) 5 (3.8%) 20 (9.1%) 4 (8.2%) 53 (4.9%) 0.005
shaking/tingling 28 (4.1%) 2 (1.5%) 13 (5.9%) 3 (6.1%) 46 (4.2%) 0.172
nausea 29 (4.2%) 2 (1.5%) 8 (3.6%) 3 (6.1%) 42 (3.9%) 0.366
Dizziness 
Cough 
Joint pain
16 (2.3%) 
17 (2.5%) 
14 (2.0%)
4 (3.1%) 
2 (1.5%) 
1 (0.8%)
12 (5.5%) 
12 (5.5%) 
14 (6.4%)
2 (4.1%) 
2 (4.1%) 
2 (4.1%)
34 (3.1%) 
33 (3.1%) 
31 (2.8%)
0.114 
0.100 
0.006
Notes: aPatients responding yes to the question: ‘Do you consider that you have had any side effects from this vaccination.’ Response options were yes or no; bany side effects 
defined from the side effect cascade plus reports of pain or discomfort; cpatients responding to the question: ‘The unusual symptom affecting me was...”: (tick all that apply) – 
Reports for 3% and above (+ significant findings). dP value from Fisher’s exact test or Kruskal–Wallis test on the difference between the 4 vaccine groups. eP value from Fisher’s 
exact test or Kruskal–Wallis test on the difference between respondents receiving h1n1p vaccine and those receiving vaccines other than h1n1p (seasonal/seasonal + other).
Table 5 Number (%) of respondents recording specific side effects after baseline influenza vaccination
Side effects H1N1p  
only
Seasonal  
only
H1N1p and  
seasonal
H1N1p/  
seasonal  
and other
Total P valueb H1N1p  
total
Not H1N1p  
total
P valuec
n (nMissing) 534 (160) 106 (29) 149 (75) 35 (15) 824 (279) 714 (246) 110 (33)
Flu-like symptomsa 128 (24.0%) 18 (17.0%) 38 (25.5%) 11 (31.4%) 195 (23.7%) 0.233 175 (24.5%) 20 (18.2%) 0.184
Absenteeism due to  
flu-like symptoms
9 (1.7%) 2 (1.9%) 5 (3.4%) 1 (2.9%) 17 (2.1%) 0.486 15 (2.1%) 2 (1.8%) 1.000
Time off due to flu-like symptoms
none 525 (98.3%) 104 (98.1%) 144 (96.6%) 34 (97.1%) 807 (97.9%) 699 (97.9%) 108 (98.2%)
One day 1 (0.2%) 1 (0.9%) 0 (0.0%) 0 (0.0%) 2 (0.2%) 1 (0.1%) 1 (0.9%)
1–3 days 5 (0.9%) 1 (0.9%) 1 (0.7%) 1 (2.9%) 8 (1.0%) 0.198 7 (1.0%) 1 (0.9%) 0.339
.3 days (0.6%) (0.0%) 4 (2.7%) 0 (0.0%) 7 (0.8%) 7 (1.0%) 0 (0.0%)
n (nMissing) 688 (6) 131 (4) 220 (4) 49 (1) 1088 (15) 949 (11) 139 (4)
Muscular side effects 131 (19.0%) 11 (8.4%) 48 (21.8%) 11 (22.4%) 201 (18.5%) 0.006 190 (20.0%) 11 (7.9%) ,0.001
Narcolepsy/seizure 42 (6.1%) 3 (2.3%) 15 (6.8%) 3 (6.1%) 63 (5.8%) 0.273 60 (6.3%) 3 (2.2%) 0.051
Notes: aPatients who had responded that they were ‘generally’ affected were asked to give more details of these side effects. Options were flu-like symptom; fever; tingling; 
disturbed sleep; loss of appetite; muscle weakness; muscle pain; shaking; dizziness; sleep problems; liver problems; weight gain; general lethargy/tiredness; feelings of extreme 
cold; sweating; allergic reaction; other. All options which applied could be ticked. Number (%) of respondents ticking flu-like symptoms are displayed with number (%) 
recording that they took any time off due to flu-like symptoms; bP value from Fisher exact test on the difference between the four vaccine groups; cP value from Fisher exact 
test on the difference between respondents receiving h1n1p vaccine and those receiving vaccines other than h1n1p (seasonal/seasonal + other).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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of discomfort/pain experienced following H1N1p   influenza 
vaccination was also significantly longer compared with sea-
sonal influenza vaccination only (P , 0.001; Table 6).
A similar incidence of side effects and local discomfort/
pain was seen after concurrent administration of the H1N1p 
influenza vaccine with the seasonal vaccine as with the 
H1N1p vaccine alone (combination vs H1N1p only, any 
side effect: 42% vs 45%, Table 4; discomfort/pain: 145/224, 
65% vs 416/694, 60%).
Because the events of side effects and discomfort/pain 
were recorded in response to separate questions, a post hoc 
sensitivity analysis was undertaken to compare any side 
effects measured from the side effect cascade (specific events 
selected for area of side effect) plus reports of discomfort/pain. 
These results are included in Table 4. (See Tables A2–A4 for 
side effect data summarized by reporting method.)
Multivariate logistic regression analyses showed that 
the female sex and influenza A (H1N1p) vaccination were 
associated with a significantly higher risk of having pain or 
discomfort, whereas the 70+ age group was associated with 
a significantly lower risk (Table 7). Influenza A (H1N1p) 
vaccination and female sex were also predictive factors in 
a vaccine recipient experiencing pain or discomfort lasting 
more than 3 days, along with the 30–49 and 50–69 age 
groups.
Table 6 number (%) of respondents with local side effects of 
discomfort and/or pain and their duration after baseline influenza 
vaccination
Discomfort/ 
pain
H1N1p  
total
Not H1N1p  
total
Overall P valueb
Presence
n (nMissing) 960 (0) 143 (0) 1103 (0)
Discomforta 377 (39.3%) 26 (18.2%) 403 (36.5%) ,0.001
Paina 212 (22.1%) 11 (7.7%) 223 (20.2%) ,0.001
Discomfort/ 
paina
589 (61.4%) 37 (25.9%) 626 (56.8%) ,0.001
none 371 (38.4%) 106 (74.1%) 477 (43.2%)
Duration
n (nMissing) 901 (59) 138 (5) 1039 (64)
,5 min 32 (3.6%) 2 (1.4%) 34 (3.3%)
.5 min, ,1 h 18 (2.0%) 1 (0.7%) 19 (1.8%) ,0.001
.1 h, ,1 day 47 (5.2%) 5 (3.6%) 52 (5.0%)
.1 day,  
,3 days
278 (30.9%) 16 (11.6%) 294 (28.3%)
.3 days 155 (17.2%) 8 (5.8%) 163 (15.7%)
Notes:  aPatients responding some discomfort or some pain (as applicable) to the 
question: ‘Did you have any pain or discomfort at the injection site.’ Response options 
were some discomfort, some pain or none. number (%) of respondents selecting some 
discomfort, some pain and some discomfort or some pain are displayed; bP value from 
Fisher exact test on the difference in presence of symptoms and duration responses 
between respondents receiving h1n1p vaccine and those receiving vaccines other 
than h1n1p (seasonal/seasonal + other).
Children
Of the 134 vaccine recipients aged under 5 years, 132 
received H1N1p vaccine (123 alone, seven in combination 
with seasonal vaccine, and two with other vaccines). In 
children under 5 years, and in those under 18 years, any side 
effects and local discomfort/pain after H1N1p vaccination 
were reported at a similar frequency to that found in the 
total population. (See Tables A5 and A6 for age group data.) 
Meaningful comparisons between children under 5 receiving 
or not receiving H1N1p vaccine cannot be made as only two 
vaccine recipients in the under 5 age group did not receive 
H1N1p. Two children in this age group were hospitalized 
after receiving the H1N1p vaccine: a 3-year old female with 
muscle pain, chest, leg, skin, and emotional side effects and 
a 1-year old female with general side effects.
Hospitalization
Most respondents experienced side effects that needed no 
action (16%) or were self-treated (20%, Table 8). However, 
eight vaccine recipients reported side effects leading to a hospi-
tal visit during the evaluation: seven after the baseline vaccina-
tion, and one at the 26-week follow up. The seven respondents 
reported 14 side effects after the baseline   vaccination. (Table 8; 
see Table A7 for further details of vaccine recipients requiring 
hospital action due to a side effect.)
side effects of special interest
The adverse events of narcolepsy and seizure are of special 
interest and there was a trend towards a higher proportion of 
H1N1p vaccine recipients reporting narcolepsy/seizures than 
with seasonal vaccine recipients (6.3% vs 2.2%, P = 0.051; 
Table 5).
One of the vaccine recipients attending hospital expe-
rienced narcolepsy. This was a 59-year-old female who 
received both H1N1p and seasonal influenza vaccine due to 
chronic disease. She also experienced general side effects 
(fever, tingling, disturbed sleep, loss of appetite, lethargy/
tiredness), head-related side effects (headache), chest-related 
side effects (chest tightness, palpitations), and emotional side 
effects (difficulty concentrating and increased irritability), 
leading to a visit to an accident and emergency department. 
The respondent was given advice only, no formal diagnosis, 
and did not require treatment or hospital admission. Only 
one other recipient of the H1N1p influenza vaccine required 
treatment from a doctor for narcolepsy/seizures. This was a 
3.5 year-old male, who experienced seizures/fits 12 weeks 
after being vaccinated against influenza A (H1N1p), who was 
treated by his doctor. Further investigation indicates that it is Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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the influenza A (H1N1p) adjuvanted split virion vaccine was 
more reactogenic than the whole virion vaccine seasonal 
vaccine.10 A previous study has also shown that injection 
site reactions were reported more frequently for recipients 
of H1N1p vaccine adjuvanted with ASO3A than without 
adjuvant, but these reactions were generally transient.11 
Mild side effects such as local discomfort/pain in the arm 
after vaccination with Pandremix have been reported in the 
manufacturer’s clinical trials, and are to be expected given 
the nature of the adjuvant used in the vaccine to stimulate a 
strong immune response.
Chronic illness may also be an important risk factor associ-
ated with injection site pain or discomfort. Interestingly, the 
analyses also showed that old age (over 70 years) was the main 
risk factor associated with a decreased likelihood of reporting 
injection site pain or discomfort after vaccination. Whether 
this is due to greater tolerance of pain or discomfort, or a 
reduction in local reactions in this age group, is unclear.
Recent reports of an increased risk of narcolepsy and 
other neurological events cannot be confirmed from this 
evaluation. There were no reported cases of Guillain–Barré 
syndrome, but with a coincident background disease rate of 
21.5 cases of 10 million individuals within 6 weeks,12 this 
was hardly unexpected.
Table 7 Multivariate regression analyses for vaccine recipients having pain or discomfort after baseline vaccination
Predictor Level Odds ratio (95% CI), P value Overall P value
Pain or discomfort
Age 0–4
5–29
30–49
50–69
70+
–
1.06 (0.55, 2.06), P = 0.862
1.21 (0.71, 2.07), P = 0.481
0.59 (0.35, 1.00), P = 0.049
0.24 (0.13, 0.43), P , 0.001
P , 0.001
sex Female 2.12 (1.62, 2.77), P , 0.001
Chronic illness special group Yes 1.21 (0.90, 1.62), P = 0.203
H1N1p flu vaccination Yes 4.69 (2.85, 7.71), P , 0.001
Seasonal flu vaccination Yes 1.06 (0.68, 1.66), P = 0.794
Previous h1n1p vaccination Yes 1.34 (0.63, 2.85), P = 0.447
Previous seasonal flu vaccination Yes 1.28 (0.82, 1.98), P = 0.276
Pain or discomfort lasting .3 days
Age 0–4 – P = 0.002
5–29 2.26 (0.89, 5.74), P = 0.085
30–49 3.44 (1.58, 7.47), P = 0.002
50–69 2.18 (0.99, 4.80), P = 0.054
70+ 1.40 (0.58, 3.40), P = 0.458
sex Female 1.90 (1.29, 2.79), P = 0.001
Chronic illness special group Yes 1.02 (0.70, 1.50), P = 0.914
H1N1p flu vaccination Yes 4.19 (1.88, 9.35), P , 0.001
Seasonal flu vaccination Yes 1.21 (0.72, 2.05), P = 0.473
Previous h1n1p vaccination Yes 1.13 (0.38, 3.39), P = 0.823
Previous seasonal flu vaccination Yes 0.95 (0.56, 1.63), P = 0.858
likely that this attendance was due to the child’s underlying 
health condition and not due to the vaccine.
No other side effects of special interest required treatment 
from a doctor or a visit to hospital.
Discussion
The PROBE methodology of an online questionnaire with 
a telephone option available for respondents provided an 
effective way of collecting safety data from a large number of 
vaccine recipients (n = 1103) during the 2009–2010 season. 
Using a simple questionnaire, which took about 5 minutes 
to complete, vaccine recipients gave demographic details 
including age and sex, confirmed the presence or absence 
of chronic illness, and provided vaccine and side effect 
information including duration and action taken due to the 
side effect.
Logistic regression analyses showed that H1N1p influ-
enza vaccination and female sex were both predictive fac-
tors in a vaccine recipient reporting a side effect of pain or 
discomfort, and of these side effects lasting for more than 
3 days. The association of the influenza A (H1N1p) vaccine 
with a higher incidence of local side effects was in line with 
data from previously reported studies, and none had a seri-
ous outcome. Clinical studies in children have shown that Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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In this evaluation, the proportion of respondents reporting 
any side effect, pain, or discomfort after vaccination with 
pandemic H1N1p vaccine was similar to that in those receiv-
ing concurrent administration of the vaccine with the seasonal 
vaccine. These results differ from those of a recently reported, 
randomized study comparing the safety and immunogenicity 
of participants receiving an H1N1p vaccine (Fluval®) or the 
H1N1p and seasonal whole-virion non-adjuvanted vaccines. 
That study showed that adverse events and pain at the injec-
tion site were reported by more recipients of both vaccines 
than by those who received the H1N1p vaccine only (any 
18% vs 10%, pain 10% vs 4%).13
strengths and limitations of the study
The strengths of using the methodology outlined in this paper 
are that it allowed patient-reported outcome data from a large 
number of vaccine recipients to be collected simply and 
quickly. When required, the respondents could be contacted 
again by email or telephone to provide longitudinal follow-up 
data, with 26-week data collected from more than half of 
the respondents in this evaluation. The option of telephone 
reporting supported by trained staff, in addition to web-based 
data collection, is important as it widens participation and 
enables evaluation of a study population that is more repre-
sentative of the target population, thus reducing bias.
Most of the methods employed by the regulatory authori-
ties in Europe or the US for monitoring adverse events still 
rely on spontaneous reporting. In contrast to spontaneous 
reporting systems, the PROBE methodology should result 
in less underreporting (as participants are already part of 
the process), should be less affected by media reporting or 
physician prejudices, and be able to calculate a numerator 
(number of events) and denominator (number of people 
exposed/vaccinated). Additionally, the databases interrogated 
by the regulatory authorities need to pre-specify the events 
of interest or be limited to generic headings which often do 
not capture the detail required. The PROBE methodology can 
also assess overall benefit:risk by obtaining quality of life 
data at the same time as adverse event and impact on work/
education data (absenteeism/presenteeism measure).
A limitation of the methodology, however, is that despite 
including data collected using a Freephone service, the 
population studied may not fully represent the views of the 
general population. There may also be some disadvantages 
from grouping together the two different modes of report-
ing and this study showed that there were differences in 
the characteristics and responses of telephone and Internet 
participants. There were also differences in the baseline 
characteristics of the populations receiving each vaccine, 
which could have contributed to the findings.
Participants were trusted to answer the questions honestly, 
particularly as they may have been influenced by negative 
publicity surrounding the use of the H1N1p influenza vac-
cine in the UK. Including questions regarding pregnancy and 
type of vaccine received, would have been useful, in order to 
provide further data. A comparison of the two novel vaccines 
used in the UK vaccination program for influenza A (H1N1p) 
may have been of interest, although respondents may not have 
been aware of which vaccine they had received.
Finally, we gathered information on absenteeism from 
work but presenteeism is gaining recognition as being a more 
useful indicator of ‘impact on work’ and we could have used 
a suitable questionnaire to assess this.
Conclusions
Safety and tolerability data from influenza vaccine recipi-
ents including young children (via parents/carers) can be 
effectively collected using an online questionnaire with 
a telephone option (PROBE). The influenza A (H1N1p) 
Table 8 number (%) of respondents recording action taken due 
to a side effect following baseline vaccination, with type of side 
effect requiring hospital use
Action taken due  
to a side effect
H1N1p total Not H1N1p  
total
Overall
n (nMissing)a 949 (11) 139 (4) 1088 (15)
  no event 535 (56.4%) 105 (75.5%) 640 (58.8%)
  nothing 165 (17.4%) 14 (10.1%) 179 (16.5%)
  self-treated 199 (21.0%) 16 (11.5%) 215 (19.8%)
  Doctor advice 27 (2.8%) 1 (0.7%) 28 (2.6%)
  Doctor treatment 17 (1.8%) 2 (1.4%) 19 (1.7%)
  hospital 6 (0.6%) 1 (0.7%) 7 (0.6%)
P valueb 0.002
  health service use 50 (5.3%) 4 (2.9%) 54 (5.0%)
P valueb 0.296
Number of side effects requiring hospital use of type reported
  Total 13 1 14
  general 4 0 4
  Muscular 1 0 1
  head 1 0 1
  Chest 2 0 2
  stomach 0 1 1
  Leg 1 0 1
  skin 1 0 1
  emotional 2 0 2
  Narcolepsy/seizure 1 0 1
Notes:  aPatients responding to the question ‘What did you do about your side 
effect.’ Options were: i did nothing; i treated it myself; i went to the doctor and was 
given advice; i went to the doctor and was given treatment; i was taken to hospital; 
bP value from Fisher exact test on the difference in responses between respondents 
receiving h1n1p vaccine and those receiving vaccines other than h1n1p (seasonal/
seasonal + other).Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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  vaccine was well tolerated, but was associated with more local 
short-term reactions than the seasonal influenza vaccine.
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Appendix 1
Description of data: statistical summaries of follow-up data 
at 6, 12 and 26 weeks, respondents recording any side effects 
and discomfort/pain split by reporting method and age groups 
Table A1 Follow-up rates by combinations of vaccines received at baseline, all patients
N H1N1 only Seasonal only H1N1 and  
seasonal
H1N1/seasonal  
and other
P valuea
6 weeks
n (nMissing) 1103 (0) 694 (0) 135 (0) 224 (0) 50 (0)
no 390 (35.4%) 229 (33.0%) 43 (31.9%) 98 (43.8%) 20 (40.0%)
Yes 713 (64.6%) 465 (67.0%) 92 (68.1%) 126 (56.2%) 30 (60.0%) 0.020
12 weeks
n (nMissing) 1103 (0) 694 (0) 135 (0) 224 (0) 50 (0)
no 457 (41.4%) 271 (39.0%) 52 (38.5%) 113 (50.4%) 21 (42.0%)
Yes 646 (58.6%) 423 (61.0%) 83 (61.5%) 111 (49.6%) 29 (58.0%) 0.023
26 weeks
n (nMissing) 1103 (0) 694 (0) 135 (0) 224 (0) 50 (0)
no 526 (47.7%) 307 (44.2%) 61 (45.2%) 130 (58.0%) 28 (56.0%) 0.003
Yes 577 (52.3%) 387 (55.8%) 74 (54.8%) 94 (42.0%) 22 (44.0%)
Note: aP value from Fisher’s exact test.
Table A2 Number (%) of respondents recording side effects following baseline influenza vaccination, by contact method
Side  
effects
H1N1  
only
Seasonal  
only
H1N1 and  
seasonal
H1N1/ 
seasonal  
and other
P valuea Overall H1N1  
total
Not  
H1N1  
total
P valueb
Web
n (nMissing) 395 (0) 83 (0) 185 (0) 34 (0) 697 (0) 607 (0) 90 (0)
Any side  
effects
163 (41.3%) 22 (26.5%) 72 (38.9%) 10 (29.4%) 0.055 267 (38.3%) 243 (40.0%) 24 (26.7%) 0.015
Discomfort  
or pain
257 (65.1%) 29 (34.9%) 125 (67.6%) 18 (52.9%) ,0.001 429 (61.5%)
Any (including  
pain/discomfort)c
291 (73.7%) 43 (51.8%) 140 (75.7%) 19 (55.9%) ,0.001 493 (70.7%) 448 (73.8%) 45 (50.0%) ,0.001
Telephone
n (nMissing) 299 (0) 52 (0) 39 (0) 16 (0) 406 (0) 353 (0) 53 (0)
Any side effects 151 (50.5%) 13 (25.0%) 22 (56.4%) 10 (62.5%) 0.002 196 (48.3%) 182 (51.6%) 14 (26.4%) 0.001
Discomfort  
or pain
159 (53.2%) 7 (13.5%) 20 (51.3%) 11 (68.8%) ,0.001 197 (48.5%)
Any (including  
pain/discomfort)c
220 (73.6%) 18 (34.6%) 27 (69.2%) 14 (87.5%) ,0.001 279 (68.7%) 260 (73.7%) 19 (35.8%) ,0.001
Notes: aP value from Fisher’s exact test on the difference between the four vaccine groups; bP value from Fisher’s exact test on the difference between respondents receiving 
h1n1 vaccine and those receiving vaccines other than h1n1 (seasonal/seasonal + other); cany side effects defined from the side effect cascade plus reports of pain or 
discomfort.
Table A3 Number (%) recording side effects following baseline influenza vaccination, by age group, and contact method
Side effects N Age at baseline (years) Age at baseline (years) Contact method
,18 $18 ,5 $5 Telephone Web
n (nMissing) 1103 (0) 157 (0) 946 (0) 132 (0) 971 (0) 406 (0) 697 (0)
Any side effectsa 463 (42.0%) 74 (47.1%) 389 (41.1%) 61 (46.2%) 402 (41.4%) 196 (48.3%) 267 (38.3%)
P valueb 0.163 P = 0.302 0.001
Discomfort or pain 626 (56.8%) 101 (64.3%) 525 (55.5%) 85 (64.4%) 541 (55.7%) 197 (48.5%) 429 (61.5%)
P valueb 0.045 P = 0.062 ,0.001
Notes: aAny side effects defined from the side effect cascade plus reports of pain or discomfort; bP value from Fisher’s exact test.
(,5 and $5, ,18, and $18 years), and individual patient 
data for patients with a side effect leading to hospitalization 
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Table A4 Number (%) recording side effects following baseline H1N1 influenza vaccination, by age, and contact method
Side effects N Age at baseline (years) Age at baseline (years) Contact method
,18 $18 ,5 $5 Telephone Web
Received H1N1 flu vaccine
n (nMissing) 960 (0) 153 (0) 807 (0) 130 (0) 830 (0) 353 (0) 607 (0)
Any side effectsa 425 (44.3%) 73 (47.7%) 352 (43.6%) 60 (46.2%) 365 (44.0%) 182 (51.6%) 243 (40.0%)
 P  valueb 0.375 0.704 0.001
Discomfort or pain 589 (61.4%) 100 (65.4%) 489 (60.6%) 85 (65.4%) 504 (60.7%) 190 (53.8%) 399 (65.7%)
 P  valueb 0.279 0.334 ,0.001
Did not receive H1N1 flu vaccine
n (nMissing) 143 (0) 4 (0) 139 (0) 2 (0) 141 (0) 53 (0) 90 (0)
Any side effectsa 38 (26.6%) 1 (25.0%) 37 (26.6%) 1 (50.0%) 37 (26.2%) 14 (26.4%) 24 (26.7%)
 P  valueb 1.000 0.462 1.000
Discomfort or pain 37 (25.9%) 1 (25.0%) 36 (25.9%) 0 (0.0%) 37 (26.2%) 7 (13.2%) 30 (33.3%)
 P  valueb 1.000 1.000 0.010
Notes: aAny side effects defined from the side effect cascade plus reports of pain or discomfort; bP value from Fisher’s exact test.
Table A5 Number (%) recording side effects following baseline influenza vaccination, by age group (,18, $18 years)
Side effects H1N1 only Seasonal  
only
H1N1 and  
seasonal
H1N1/seasonal  
and other
P valuea Overall H1N1  
total
Not  
H1N1 total
P valueb
Aged ,18 years
n (nMissing) 138 (0) 4 (0) 12 (0) 3 (0) 157 (0) 153 (0) 4 (0)
Any – – – – 74 (47.1%) 73 (47.7%) 1 (25.0%) 0.623
Discomfort/pain 90 (65.2%) 1 (25.0%) 8 (66.7%) 2 (66.7%) 0.428 101 (64.3%) – –
Any (including  
pain/discomfort)c
109 (79.0%) 2 (50.0%) 10 (83.3%) 2 (66.7%) 0.352 123 (78.3%) 121 (79.1%) 2 (50.0%) 0.205
n (nMissing) 138 (0) 4 (0) 12 (0) 3 (0) 157 (0) 153 (0) 4 (0)
narcolepsy/ 
seizures
17 (12.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.719 17 (10.8%) 17 (11.1%) 0 (0.0%) 1.000
Aged $18 years
n (nMissing) 556 (0) 131 (0) 212 (0) 47 (0) 946 (0) 807 (0) 139 (0)
Any – – – – 389 (41.1%) 352 (43.6%) 37 (26.6%) ,0.001
Discomfort/pain 326 (58.6%) 35 (26.7%) 137 (64.6%) 27 (57.4%) ,0.001 525 (55.5%) – –
Any (including  
pain/discomfort)c
402 (72.3%) 59 (45.0%) 157 (74.1%) 31 (66.0%) ,0.001 649 (68.6%) 587 (72.7%) 62 (44.6%) ,0.001
n (nMissing) 550 (6) 127 (4) 208 (4) 46 (1) 931 (15) 796 (11) 135 (4)
narcolepsy/ 
seizures
25 (4.5%) 3 (2.4%) 15 (7.2%) 3 (6.5%) 0.185 46 (4.9%) 43 (5.4%) 3 (2.2%) 0.135
Notes: aP value from Fisher’s exact test on the difference between the four vaccine groups;  bP value from Fisher’s exact test on the difference between respondents 
receiving h1n1 vaccine and those receiving vaccines other than h1n1 (seasonal/seasonal + other); cany side effects defined from the side effect cascade plus reports of pain   
or discomfort.Therapeutics and Clinical Risk Management
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Table A7 Patients with a side effect leading to hospitalization
Subject Age  
(years)/sex
Influenza 
vaccine  
history
Influenza  
vaccine received 
at baseline
Reason given  
for hospitalization
Survey  
time
Subsequent  
vaccinations
Co-existing 
conditions
347 58/female none seasonal only stomach Baseline no subsequent vaccinations  
(up to week 12)
none known
376 3/female Prior  
seasonal
h1n1 only Muscle 
Chest 
Legs 
skin 
emotional
Baseline no subsequent data Cerebral  
Palsy
419 42/male none h1n1 and  
seasonal
Legs Baseline h1n1 at 6 weeks 
no subsequent vaccinations  
(up to week 12)
Multiple 
sclerosis
493 61/female Prior  
seasonal
h1n1 only Chest 26 weeks no subsequent vaccinations  
(up to week 26)
none known
585 59/female none h1n1 and seasonal general 
head 
Chest 
emotional 
Narcolepsy/seizures
Baseline no subsequent vaccinations 
(up to week 26)
Chronic 
disease 
group 
Asthma
743a 55/female Prior  
seasonal
h1n1 only general Baseline no subsequent vaccinations 
(up to week 26)
984a 1/female Prior h1n1 h1n1 only general Baseline no subsequent vaccinations  
(up to week 26)
1124 45/female Prior  
seasonal
h1n1 only general Baseline no subsequent data none known
Note: aFollow-up contact reports have indicated that patients 743 and 984 did not attend hospital in relation to their vaccine and may be classified as ‘incorrect reports’.
Table A6 Number (%) recording side effects following baseline influenza vaccination, by age group (,5, $5 years)
Side effects H1N1 only Seasonal  
only
H1N1 and  
seasonal
H1N1/seasonal  
and other
P valuea Overall H1N1 total Not H1N1  
total
P valueb
Aged ,5 years
n (nMissing) 123 (0) 2 (0) 5 (0) 2 (0) 132 (0) 130 (0) 2 (0)
Any – – – – 61 (46.2%) 60 (46.2%) 1 (50.0%) 1.000
Discomfort/pain 81 (65.9%) 0 (0.0%) 3 (60.0%) 1 (50.0%) 0.294 85 (64.4%) – –
Any (including  
pain/discomfort)c
97 (78.9%) 1 (50.0%) 4 (80.0%) 1 (50.0%) 0.365 103 (78.0%) 102 (78.5%) 1 (50.0%) 0.392
Aged $5 years
n (nMissing) 571 (0) 133 (0) 219 (0) 48 (0) 971 (0) 830 (0) 141 (0)
Any – – – – 402 (41.4%) 365 (44.0%) 37 (26.2%) ,0.001
Discomfort/pain 335 (58.7%) 36 (27.1%) 142 (64.8%) 28 (58.3%) ,0.001 541 (55.7%) – –
Any (including  
pain/discomfort)c
414 (72.5%) 60 (45.1%) 163 (74.4%) 32 (66.7%) ,0.001 669 (68.9%) 606 (73.0%) 63 (44.7%) ,0.001
Notes: aP value from Fisher’s exact test on the difference between the four vaccine groups; bP value from Fisher’s exact test on the difference between respondents receiving h1n1 
vaccine and those receiving vaccines other than h1n1 (seasonal/seasonal + other); cany side effects defined from the side effect cascade plus reports of pain or discomfort.